Healthcare Service Cost and Utilization Evidence Summary

HP+ conducted a systematic review of studies on cost reimbursement guidelines and synthesized resulting policy recommendations as an evidence summary. The analysis was conducted as a follow-on to a prior HP+ analysis, which identified potential cost inefficiencies plaguing Mali’s health system, such as high utilization of brand-name pharmaceuticals despite the availability of generic drugs. The policy recommendations provided in this summary provide an evidence base for experts from Mali’s National Health Insurance Fund to guide revisions to cost reimbursement guidelines and facilitate the advancement of the revision process.

Information presented on this website is considered public information and may be distributed or copied freely unless identified as being subject to copyright protection.